Suppr超能文献

腱鞘或弥漫型非手术性巨细胞瘤:MRI 或 18F-FDG PET/CT 能否准确预测长期预后?

Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?

机构信息

Department of Nuclear Medicine, IUCT-Oncopole/Institut Claudius Regaud, 31100, Toulouse, France,

出版信息

Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):397-408. doi: 10.1007/s00259-014-2938-9. Epub 2014 Nov 1.

Abstract

PURPOSE

To investigate whether MRI (RECIST 1.1, WHO criteria and the volumetric approach) or (18)F-FDG PET/CT (PERCIST 1.0) are able to predict long-term outcome in nonsurgical patients with giant cell tumour of the tendon sheath or of the diffuse type (GCT-TS/DT).

METHODS

Fifteen "nonsurgical" patients with a histological diagnosis of GCT-TS/DT were divided into two groups: symptomatic patients receiving targeted therapy and asymptomatic untreated patients. All 15 patients were evaluated by MRI of whom 10 were treated, and a subgroup of 7 patients were evaluated by PET/CT of whom 4 were treated. Early evolution was assessed according to MRI and PET/CT scans at baseline and during follow-up. Cohen's kappa coefficient was used to evaluate the degree of agreement between PERCIST 1.0, RECIST 1.1, WHO criteria, volumetric approaches and the reference standard (long-term outcome, delay 505 ± 457 days). The response rate in symptomatic patients with GCT-TS/DT receiving targeted therapy was also assessed in a larger population that included additional patients obtained from a review of the literature.

RESULTS

The kappa coefficients for agreement between RECIST/WHO/volumetric criteria and outcome (15 patients) were respectively: 0.35 (p = 0.06), 0.26 (p = 0.17) and 0.26 (p = 0.17). In the PET/CT subgroup (7 patients), PERCIST was in perfect agreement with the late symptomatic evolution (kappa = 1, p < 0.05). In the treated symptomatic group including the additional patients from the literature the response rates to targeted therapies according to late symptomatic assessment, and PERCIST and RECIST criteria were: 65 % (22/34), 77 % (10/13) and 26 % (10/39).

CONCLUSION

(18)F-FDG PET/CT with PERCIST is a promising approach to the prediction of the long-term outcome in GCT-TS/DT and may avoid unnecessary treatments, toxicity and costs. On MRI, WHO and volumetric approaches are not more effective than RECIST using the current thresholds.

摘要

目的

探讨 MRI(RECIST 1.1、WHO 标准和体积法)或(18)F-FDG PET/CT(PERCIST 1.0)是否能够预测腱鞘巨细胞瘤或弥漫型(GCT-TS/DT)非手术患者的长期预后。

方法

15 例经组织学诊断为 GCT-TS/DT 的“非手术”患者分为两组:接受靶向治疗的有症状患者和未接受治疗的无症状患者。所有 15 例患者均接受 MRI 评估,其中 10 例接受治疗,7 例患者接受 PET/CT 评估,其中 4 例接受治疗。根据基线和随访期间的 MRI 和 PET/CT 扫描评估早期演变。采用 Cohen's kappa 系数评估 PERCIST 1.0、RECIST 1.1、WHO 标准、体积方法与参考标准(505±457 天的长期结局)之间的一致性程度。还在一个更大的患者群体中评估了接受靶向治疗的 GCT-TS/DT 有症状患者的反应率,该群体还包括从文献回顾中获得的其他患者。

结果

RECIST/WHO/体积标准与结局(15 例患者)之间的一致性 kappa 系数分别为:0.35(p=0.06)、0.26(p=0.17)和 0.26(p=0.17)。在 PET/CT 亚组(7 例患者)中,PERCIST 与晚期有症状演变完全一致(kappa=1,p<0.05)。在包括文献中额外患者的治疗有症状组中,根据晚期有症状评估、PERCIST 和 RECIST 标准,靶向治疗的反应率分别为:65%(22/34)、77%(10/13)和 26%(10/39)。

结论

(18)F-FDG PET/CT 联合 PERCIST 是预测 GCT-TS/DT 长期结局的一种很有前途的方法,可能避免不必要的治疗、毒性和成本。在 MRI 上,与当前阈值相比,WHO 和体积方法并不比 RECIST 更有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验